AdaptHealth sharply reduced its full-year 2026 adjusted EBITDA guidance from $680-$730 million to approximately $490-$520 million, causing its stock to fall by up to 26%. The company initially cited elevated labor costs normalizing, but later attributed the cut to factors including a divestiture, contract changes, and pricing issues. This sudden downgrade has triggered an investor investigation into whether AdaptHealth misled shareholders about its financial outlook. Investors who suffered losses are encouraged to participate in the ongoing investigation.
AdaptHealth reported a challenging Q2 with a loss of $1.07 per share and a $106 million revenue shortfall, prompting a lowered profitability outlook. Despite these setbacks, its core Sleep Health and Respiratory Health segments grew strongly, with ne...
AdaptHealth's shares dropped over 30% following a disappointing Q2 report, including a $1.07 loss per share and missing revenue by $106 million. The company is selling its low-margin diabetes business to Cardinal Health for $235 million to concentrat...
Stocks fell sharply due to various factors including a 58.71% drop in the Defiance Daily Target 2x Short PLTR ETF, driven by strong gains in Palantir Technologies, which the ETF inversely tracks. AdaptHealth shares dropped 38.09% amid a legal investi...
Holzer & Holzer, LLC announced an investigation into AdaptHealth Corp. following the company's revised financial guidance and second quarter 2026 results. AdaptHealth reported a decrease in cash flow from operations to $239 million year-to-date 2026,...
